QIAGEN

Digital PCR takes forever and is super complicated. You can be on either team NGS or dPCR. qPCR has been around for ages, so it’s more trustworthy. Heard some of these before, but questioned their validity🤔? Then you might be interested in our list of common dPCR myths, assembled only to be disassembled in the quest for dPCR justice⚖️. Check out the very real dPCR misconceptions our team encounters in labs across the world. And see how our experts would answer if they had a loudspeaker📢 loud enough to reach all dPCR current and potential users. #DigitalPCR #dPCR #qPCR #Multiplex #GeneExpression 

What if clinical labs could increase their syndromic testing capabilities without adding additional complexity? We’ve made that possible with our fully automated, high-throughput syndromic testing platform, QIAstat-Dx Rise. An expanded testing menu, now including FDA-cleared gastrointestinal (GI) panels, enables labs to consolidate both respiratory (RP) and GI pathogen testing into a single platform for comprehensive disease insights. What does this mean for your lab? ✅   Accurate detection of the most clinically-relevant RP and GI pathogens ✅  Testing flexibility with access to both extended and targeted syndromic panels  ✅  True walkaway freedom due to minimal hands-on time  ✅  Results in about an hour to support timely clinical decisions Discover how QIAstat Dx-Rise can transform gastrointestinal care. ➡️ https://lnkd.in/ehDgriJz

How many steps in your cell and gene therapy (CGT) workflow are you truly confident in and how many are you just hoping will work? In cell and gene therapy development, your workflow needs to deliver every step of the way. At ISCT 2026 (May 6-9, Dublin), explore how automation and digital PCR can help you improve consistency, reduce variability and move forward with confidence. 🔬 QIAsprint® Connect: Automated high-throughput nucleic acid extraction system that offers compliance-ready flexibility for downstream molecular analysis 📊 QIAcuity® Digital PCR: Precise, reproducible quantification for CGT analytics, enabling confident assessment of critical quality attributes 📍 Booth 1908 🎤 May 7 | Global Showcase presentation on CAR T analytics presented by Anida Mesihovic Karamitsos, PhD (QIAGEN) and Arvind M Padma, PhD (CCRM Nordic)

Happy DNA Day!   Let’s take a moment to celebrate all the amazing things we’ve achieved with this molecule. Like improving detection and treatment of disease, analyzing plant genomes, catching criminals, sequencing ancient DNA from mammoths, investigating microbiomes, testing food safety and even using DNA to store data.   How familiar are you with all of these achievements? Pick your brain in a fun game of three truths and a lie and try to identify the incorrect DNA fact below.   And here’s one more fact...We, at QIAGEN, have been working with DNA for 40 years. In this time, we’ve put together DNA extraction kits that are recognized, used and loved by researchers all over the world. Interested in testing some of these as trial kits during our DNA Day special? Build on celebration and find out more ➡️ https://lnkd.in/dMkbU7hD

What does a scientist really do all day? Today, a group of curious young minds came to find out. For Girls' & Boys' Day 2026, we welcomed students into our labs, production areas and offices at QIAGEN. They explored engineering, research, communications and the many ways science becomes real-world impact. They asked smart questions. They challenged assumptions. They reminded us why curiosity never gets old. Thank you to every QIAGENer who shared their time and passion today. The future of science starts when young people can see it, touch it and imagine themselves in it.

What if switching to more sustainable lab consumables required...absolutely nothing from you?   This Earth Day, we're proving it's possible. That's the idea behind our Biobased Rotor Adapters for our QIAcube Connect System. Same product. Same performance – no revalidation, no workflow changes, no compromise needed. Just made from renewable raw materials with a significantly lower CO2 footprint.   Sustainability isn't just an add-on. It's built into the way we innovate. Learn more ➡️ https://lnkd.in/dfYrzuJq

Reporting from American Association for Cancer Research 2026, where the energy across the oncology community has been impossible to miss. From meaningful conversations to the latest technologies on display, this year’s meeting reflects just how quickly the field continues to evolve and how much momentum is building behind the next wave of discoveries. For us at QIAGEN, it’s an opportunity to be part of that exchange: to connect with researchers, share perspectives and contribute to the progress shaping the future of cancer research. We leave AACR inspired, energized and excited to bring a glimpse of that experience to you. Whether you were there with us or following from afar, here's a highlights video to give you a feel for the energy, conversations and discoveries that made AACR 2026 one to remember.

ESCMID Global 2026 is always about more than diagnostics. It is about the people behind the science and progress that are making improvements in the lives of patients around the world.   Conversations with clinicians, lab leaders and researchers at the event in Munich have focused on the areas that matter most: syndromic testing, tuberculosis management and the growing need for flexible lab-developed solutions.   A key highlight is the launch of our QIAstat-Dx BCID GPF Plus AMR Panel, expanding our syndromic testing portfolio into bloodstream infection applications with an CE-IVDR certified panel for use on QIAstat-Dx.   Our team has also been showcasing our broader infectious disease portfolio led by QuantiFERON-TB Gold Plus – the clinically proven, globally trusted choice for TB infection testing, with over 125 million patients tested since launch.    If you are still in Munich at ESCMID, we would love to see you. Find us at Hall B1, Booth C20.

We are expanding into bloodstream infection syndromic testing with the launch of the QIAstat-Dx BCID GPF Plus AMR Panel, now CE-IVDR certified. Learn more ➡️ https://lnkd.in/dRa6EtRD ✅ Detects 20 gram-positive bacterial and fungal pathogen targets (GPF) and 10 antimicrobial resistance (AMR) markers from positive blood cultures and pure colonies ✅ Returns results in about one hour, enabling faster clinical decision-making, antimicrobial stewardship and infection control ✅ Builds on our QIAstat-Dx portfolio in respiratory, gastrointestinal and meningitis/encephalitis testing, now reaching into bloodstream infection applications We are excited to bring this innovation to the ESCMID Global 2026 Congress in Munich (April 17-21), where we will also highlight our broader infectious disease portfolio including QuantiFERON-TB Gold Plus and additional technologies supporting laboratory workflows and clinical decision-making. With more than 5,200 QIAstat-Dx instruments placed in over 100 countries, we continue to strengthen our syndromic testing capabilities to support laboratories and clinicians worldwide.

Studying cancer genomics is a bit like zooming in on a high-resolution image. The closer you look, the more meaningful details begin to emerge. Our hybrid capture-based comprehensive genomic profiling panels help bring those details into sharp focus by examining DNA and RNA biomarkers across 724 genes, including TMB, MSI and HRD. A single, consolidated workflow that zooms in on multiple genomic details simultaneously. The result: A broader view of tumor biology. But science moves quickly. How can you keep up with emerging targets and evolving guidelines and update assay content easily? Flexible customization is the answer. Our NGS solutions are readily customizable, allowing you to maintain momentum in your research and develop a holistic understanding of cancer biology. Learn more ➡️ https://lnkd.in/dGntpWKF